Table 1 Content of multidisciplinary quantitative evaluation forms
Sector | Items | Content |
|---|---|---|
1. Infectious disease management | 1.1 Multidisciplinary team construction | Staffing and training of infectious disease specialists, clinical pharmacists in infection, clinical microbiology professionals, hospital infection prevention professionals; organizational structure and interdisciplinary collaboration mechanisms. |
1.2 Procurement | Supply catalogues for targeted antibiotics (e.g., penicillin, benzylpenicillin, furazolidone, compound sulfamethoxazole, fluorouracil, cefazolin, cefuroxime [injection]). | |
1.3 β-lactam skin test | Implementation of standardized Cephalosporin allergy testing protocols and clinical practices. | |
2. Antibacterial usage surveillance | 2.1 Data reporting | Timeliness and completeness of antibacterial usage data submission (e.g., outpatient, inpatient, emergency). |
2.2 Management practices | Regulatory compliance in antibacterial formulary development, temporary procurement procedures, and documentation of antibacterial prescription reviews. | |
2.3 Antibacterial usage indicators | Prescription rate and usage intensity of antibacterial use in outpatient, emergency, and inpatient settings. | |
2.4 Focused antibiotics usage intensity | Usage intensity of tigecycline, carbapenems, 3rd-generation cephalosporins, cephalosporin/enzyme inhibitors, and quinolones compared to national averages. | |
3. Antibacterial resistance surveillance | 3.1 Specimen quality & quantity | Proportion of outpatient specimens, blood cultures, and cerebrospinal fluid samples meeting quality standards; annual bacterial strain counts. |
3.2 Antibacterial susceptibility testing | Completeness of antimicrobial susceptibility panels for Enterobacteriaceae, P. aeruginosa, A. baumannii, S. aureus, Enterococcus, S. pneumoniae, Salmonella, Shigella, Haemophilus influenzae, and Campylobacter. | |
3.3 Focused drug-resistance pathogens | Detection rates of MRSA, VREFM, CRKP, CRPA, CRAB, and 3GCREC compared to national averages. | |
4. Fungal diseases surveillance | 4.1 Participation & data quality | Retrospective mycological studies, active surveillance of fungal bloodstream infections, and data accuracy in reporting. |
4.2 Training | Participation of clinicians and laboratory staff in online training programs. | |
4.3 Diagnostic capability | Proficiency in microscopy (e.g., Gram staining, KOH mounts), fungal culture/identification, antifungal susceptibility testing, and quality control (e.g., internal/external assessments). | |
5. Hospital infection surveillance | 5.1 Informatization | Organizational structure of infection control departments, functionality of surveillance information systems, and completeness of prevalence data reporting. |
5.2 Hospital infection indicators | Incidence of VAP, CRUTI, and CLABSI; perioperative antimicrobial prophylaxis compliance; hand hygiene compliance; sample submission; prevalence of hospital infection. | |
5.3 Infection prevention & control | Isolation protocols, identification accuracy, and single-use equipment management for multidrug-resistant infections. |